Efficacy and cost of atypical antipsychotics in treatment and management of dementia

There is a significant lack of pharmacoeconomic research on using atypical antipsychotics for the treatment of dementia. Further comprehensive research should be carried out into this field. We have found a good number of studies exploring the effectiveness and cost-effectiveness of atypical antipsychotics for schizophrenia using a decision-analytical model. However, there were only a couple of studies which have focused on the use of AAs for dementia and that too with several limitations. Therefore, it is pertinent to undertake further systematic and comprehensive research on the safety and efficacy of atypical antipsychotics for the management of BPSD. This is essential in improving clinical practice and suggesting better pathways for dementia treatment as well as in mitigating the adverse impacts on the quality of life of patients and their caregivers.